Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Uncoupling protein 2 regulates metabolic reprogramming and fate of antigen-stimulated CD8+ T cells.

Chaudhuri L, Srivastava RK, Kos F, Shrikant PA.

Cancer Immunol Immunother. 2016 Jul;65(7):869-74. doi: 10.1007/s00262-016-1851-4. Epub 2016 Jun 6. Review.

2.

Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.

Matsuzaki J, Tsuji T, Luescher IF, Shiku H, Mineno J, Okamoto S, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Sci Rep. 2015 Oct 8;5:14896. doi: 10.1038/srep14896.

3.

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.

Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K.

Oncotarget. 2015 Sep 29;6(29):27359-77. doi: 10.18632/oncotarget.4751.

4.

β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10.

Fu C, Liang X, Cui W, Ober-Blöbaum JL, Vazzana J, Shrikant PA, Lee KP, Clausen BE, Mellman I, Jiang A.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2823-8. doi: 10.1073/pnas.1414167112. Epub 2015 Feb 17.

5.

Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.

Matsuzaki J, Tsuji T, Luescher I, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Cancer Immunol Res. 2014 Apr;2(4):341-50. doi: 10.1158/2326-6066.CIR-13-0138. Epub 2013 Dec 17.

6.

β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.

Liang X, Fu C, Cui W, Ober-Blöbaum JL, Zahner SP, Shrikant PA, Clausen BE, Flavell RA, Mellman I, Jiang A.

J Leukoc Biol. 2014 Jan;95(1):179-90. doi: 10.1189/jlb.0613330. Epub 2013 Sep 10.

PMID:
24023259
8.

A unique form of haptoglobin produced by murine hematopoietic cells supports B-cell survival, differentiation and immune response.

Huntoon KM, Russell L, Tracy E, Barbour KW, Li Q, Shrikant PA, Berger FG, Garrett-Sinha LA, Baumann H.

Mol Immunol. 2013 Oct;55(3-4):345-54. doi: 10.1016/j.molimm.2013.03.008. Epub 2013 Mar 30.

9.

Rapamycin: A rheostat for CD8(+) T-cell-mediated tumor therapy.

Srivastava RK, Utley A, Shrikant PA.

Oncoimmunology. 2012 Oct 1;1(7):1189-1190.

10.

Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation.

Qian F, Liao J, Villella J, Edwards R, Kalinski P, Lele S, Shrikant P, Odunsi K.

Cancer Immunol Immunother. 2012 Nov;61(11):2013-20. doi: 10.1007/s00262-012-1265-x. Epub 2012 Apr 22.

PMID:
22527253
11.

Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.

Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, Jäger E.

Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5797-802. doi: 10.1073/pnas.1117208109. Epub 2012 Mar 27.

12.

Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation.

Rao RR, Li Q, Gubbels Bupp MR, Shrikant PA.

Immunity. 2012 Mar 23;36(3):374-87. doi: 10.1016/j.immuni.2012.01.015. Epub 2012 Mar 15.

13.

Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity.

Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W, Shrikant PA.

J Immunol. 2012 Apr 1;188(7):3080-7. doi: 10.4049/jimmunol.1103365. Epub 2012 Feb 29.

14.

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R.

PLoS One. 2012;7(1):e30815. doi: 10.1371/journal.pone.0030815. Epub 2012 Jan 27.

15.

A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity.

Li Q, Rao RR, Araki K, Pollizzi K, Odunsi K, Powell JD, Shrikant PA.

Immunity. 2011 Apr 22;34(4):541-53. doi: 10.1016/j.immuni.2011.04.006.

16.

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.

Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL.

Br J Cancer. 2011 Feb 15;104(4):643-52. doi: 10.1038/bjc.2011.15. Epub 2011 Feb 1.

17.

Fine-tuning CD8(+) T cell functional responses: mTOR acts as a rheostat for regulating CD8(+) T cell proliferation, survival and differentiation?

Rao RR, Li Q, Shrikant PA.

Cell Cycle. 2010 Aug 1;9(15):2996-3001. doi: 10.4161/cc.9.15.12359. Epub 2010 Aug 12.

PMID:
20699660
18.

NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses.

Wadle A, Mischo A, Strahl S, Nishikawa H, Held G, Neumann F, Wullner B, Fischer E, Kleber S, Karbach J, Jager E, Shiku H, Odunsi K, Shrikant PA, Knuth A, Cerundolo V, Renner C.

Yeast. 2010 Nov;27(11):919-31. doi: 10.1002/yea.1796.

19.

Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype.

Yeh N, Glosson NL, Wang N, Guindon L, McKinley C, Hamada H, Li Q, Dutton RW, Shrikant P, Zhou B, Brutkiewicz RR, Blum JS, Kaplan MH.

J Immunol. 2010 Aug 15;185(4):2089-98. doi: 10.4049/jimmunol.1000818. Epub 2010 Jul 12.

20.

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K.

Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80. doi: 10.1073/pnas.1003345107. Epub 2010 Apr 12.

21.

The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin.

Rao RR, Li Q, Odunsi K, Shrikant PA.

Immunity. 2010 Jan 29;32(1):67-78. doi: 10.1016/j.immuni.2009.10.010. Epub 2010 Jan 7.

22.

Regulating functional cell fates in CD8 T cells.

Shrikant PA, Rao R, Li Q, Kesterson J, Eppolito C, Mischo A, Singhal P.

Immunol Res. 2010 Mar;46(1-3):12-22. doi: 10.1007/s12026-009-8130-9. Review.

23.

Antigen-induced Erk1/2 activation regulates Ets-1-mediated sensitization of CD8+ T cells for IL-12 responses.

Li Q, Eppolito C, Odunsi K, Shrikant PA.

J Leukoc Biol. 2010 Feb;87(2):257-63. doi: 10.1189/jlb.0409221. Epub 2009 Oct 20.

24.

Introduction to immunology at Roswell Park Cancer Institute.

Shrikant P, Lee K.

Immunol Res. 2010 Mar;46(1-3):1-3. doi: 10.1007/s12026-009-8132-7. No abstract available.

PMID:
19830394
25.

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.

Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD Jr, Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, Beck A, Liao J, Cheney R, Moysich K, Lele S, Shrikant P, Old LJ, Odunsi K.

Cancer Res. 2009 Jul 1;69(13):5498-504. doi: 10.1158/0008-5472.CAN-08-2106. Epub 2009 Jun 2.

26.

Angiostatic activity of the antitumor cytokine interleukin-21.

Castermans K, Tabruyn SP, Zeng R, van Beijnum JR, Eppolito C, Leonard WJ, Shrikant PA, Griffioen AW.

Blood. 2008 Dec 15;112(13):4940-7. doi: 10.1182/blood-2007-09-113878. Epub 2008 May 30.

27.

The acute phase protein haptoglobin regulates host immunity.

Huntoon KM, Wang Y, Eppolito CA, Barbour KW, Berger FG, Shrikant PA, Baumann H.

J Leukoc Biol. 2008 Jul;84(1):170-81. doi: 10.1189/jlb.0208100. Epub 2008 Apr 24.

28.

Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1.

Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatic S, Old LJ, Odunsi K.

Cancer Immunol Immunother. 2008 Aug;57(8):1185-95. doi: 10.1007/s00262-008-0450-4. Epub 2008 Feb 6.

PMID:
18253733
29.

Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs.

Tosello V, Odunsi K, Souleimanian NE, Lele S, Shrikant P, Old LJ, Valmori D, Ayyoub M.

Clin Immunol. 2008 Mar;126(3):291-302. doi: 10.1016/j.clim.2007.11.008. Epub 2007 Dec 31.

PMID:
18166500
30.

Characterizing host immune responses by monitoring fluorescently marked cells.

Mischo A, Eppolito C, Li Q, Shrikant PA.

Immunol Invest. 2007;36(5-6):791-805. No abstract available.

PMID:
18161529
31.

B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.

Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, Haicheur N, Amessou M, Herbelin A, Langlade-Demoyen P, Fridman WH, Lemonnier F, Johannes L, Tartour E.

J Immunol. 2007 Sep 1;179(5):3371-9.

32.

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.

Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S.

Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42. Epub 2007 Jul 25.

33.

IL-12-programmed long-term CD8+ T cell responses require STAT4.

Li Q, Eppolito C, Odunsi K, Shrikant PA.

J Immunol. 2006 Dec 1;177(11):7618-25.

34.

Aspergillus fumigatus extract differentially regulates antigen-specific CD4+ and CD8+ T cell responses to promote host immunity.

Tao J, Segal BH, Eppolito C, Li Q, Dennis CG, Youn R, Shrikant PA.

J Leukoc Biol. 2006 Sep;80(3):529-37. Epub 2006 Jun 22.

PMID:
16793916
35.

Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery.

Bolesta E, Kowalczyk A, Wierzbicki A, Eppolito C, Kaneko Y, Takiguchi M, Stamatatos L, Shrikant PA, Kozbor D.

J Immunol. 2006 Jul 1;177(1):177-91.

36.

The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.

Vingert B, Adotevi O, Patin D, Jung S, Shrikant P, Freyburger L, Eppolito C, Sapoznikov A, Amessou M, Quintin-Colonna F, Fridman WH, Johannes L, Tartour E.

Eur J Immunol. 2006 May;36(5):1124-35.

37.
38.

Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer.

Hylander B, Repasky E, Shrikant P, Intengan M, Beck A, Driscoll D, Singhal P, Lele S, Odunsi K.

Gynecol Oncol. 2006 Apr;101(1):12-7. Epub 2005 Nov 2.

PMID:
16263157
39.

IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21.

Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA.

J Immunol. 2004 Jul 15;173(2):900-9.

40.
41.
42.
43.

Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response.

Tham EL, Shrikant P, Mescher MF.

J Immunol. 2002 Feb 1;168(3):1190-7.

44.
46.

The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation.

Shrikant P, Benveniste EN.

J Immunol. 1996 Sep 1;157(5):1819-22. Review.

PMID:
8757296
47.

Stimulus-specific inhibition of intracellular adhesion molecule-1 gene expression by TGF-beta.

Shrikant P, Lee SJ, Kalvakolanu I, Ransohoff RM, Benveniste EN.

J Immunol. 1996 Jul 15;157(2):892-900.

PMID:
8752943
49.

Second messenger systems in the regulation of cytokines and adhesion molecules in the central nervous system.

Benveniste EN, Huneycutt BS, Shrikant P, Ballestas ME.

Brain Behav Immun. 1995 Dec;9(4):304-14. Review.

PMID:
8903848
50.

Intercellular adhesion molecule-1 gene expression by glial cells. Differential mechanisms of inhibition by IL-10 and IL-6.

Shrikant P, Weber E, Jilling T, Benveniste EN.

J Immunol. 1995 Aug 1;155(3):1489-501.

PMID:
7636212

Supplemental Content

Loading ...
Support Center